Nov 19 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX PROVIDES CORPORATE UPDATE
* HEMOSTEMIX INC - KYLE MAKOFKA HAS RESIGNED AS CO'S CEO
* HEMOSTEMIX INC - COMMENCED SEARCH FOR A SUITABLE REPLACEMENT AND WILL ANNOUNCE ANY APPOINTMENT IN DUE COURSE
* HEMOSTEMIX INC - ENTERED INTO AN AMENDED LICENSE AGREEMENT DATED SEPT 30, 2019 WITH ASPIRE HEALTH SCIENCE, LLC
* HEMOSTEMIX - AMENDED LICENSE TO AMEND ORIGINAL LICENSE GRANTING ASPIRE EXCLUSIVE RIGHTS TO USE, SELL, IMPORT ACP-01 IN SOME JURISDICTIONS
* HEMOSTEMIX- UNDER TERMS, CO IS ENTITLED TO RECEIVE AN UP-FRONT PAYMENT OF $1 MILLION FROM ASPIRE WITHIN 30 DAYS OF DATE FIRST WRITTEN IN AMENDED LICENSE
* HEMOSTEMIX- CO,ASPIRE MAY TERMINATE AMENDED LICENSE IF THERE IS BREACH OF MATERIAL CONDITION/ BANKRUPTCY/INSOLVENCY OF CO, ASPIRE TO AMENDED LICENSE
* HEMOSTEMIX INC - WILL CONTINUE TO SEEK OTHER MEANS TO REDUCE COSTS AND WILL CONTINUE TO LOOK AT AVAILABLE FINANCING AND RESTRUCTURING ALTERNATIVES